Lenvatinib Packaging for Endometrial Cancer Tied to $168 Million in Overspending
PHOENIX — Dose-specific packaging could potentially result in substantial excess spending on lenvatinib (Lenvima) for endometrial cancer, a researcher reported. Patients and payers may be on the hook for as much as $168 million in annual overspending for dose reductions for the disease — spending that could be avoided with different packaging, reported Emeline Aviki, […]